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SYNTHESIS OF CARBAPENEMSWITH A RXCH2-SUBSTITUENT IN THE 3-POSITION
Johannes G. de Vries*1 , Gerhard Sigmund, and Georg Vorisek
Sandoz Forschungsinstitut, Brunnerstraße 59, A-1235 Vienna, Austria
Abstract - Carbapenems 6 were prepared by reacting mercaptans with bromoketone 3
followed by a Wittig sequence, or better through advanced intermediate 9. The car-
bapenem carboxylates were chemically unstable; stability was not improved by chan-
ging the oxidation state of sulfur.
Ever since the discovery of thienamycin (la) a large number of analogues have been synthe-
IV
sized in an attempt to improve the chemical and metabolical instability of thienamycin while re-
taining its potent antibacterial activity2. Our efforts in this area have been concentrated on
carbapenems with an R-I-fluoroethyl side chain in the 6-position3. In this paper we report our
synthetic work on carbapenems bearing a CH2XR side chain in the 3-position
4: we hoped that
insertion of a methylene group in between nucleus and sulfur side chain would provide addi-
tional chemical and metabolic stability. From the viewpoint of synthetic efficiency introduction
of the variable RX group should occur as late as possible in the synthetic sequence. We there-
fore chose 3-acetoxymethylcarbapenem ester 6a as intermediate, based upon the knowledge that
3-acetoxymethylcephalosporins react with mercaptans to give the thio substituted analogues5.
Starting with acid 23a,b we were able to synthesize the bromoketone 36 (41%7, mp 71-73°C) by~ ~
a Nierenstein sequence8 (see Reaction Conditions). Reaction with NaOAc in DMF gave the acet-
oxy compound 4a in 88% yield which was transformed into the desired 3-acetoxymethylcarba-
penem 6a by the Wittig procedure developed by Woodward9 (44%over 4 steps). Unfortunately,~
reaction of 6a with lithium benzyl sulfide (THF, -30°C) led to unidentifiable products and re-
action with PhCH2SH/Et3N (CH2CI2, RT) gave only recovered 6a. Addition of Pd(Ph3P)4 to the
latter reaction had no beneficial effect. Before investigating other strategies we decided to
synthesize one representative of 6 by an alternative route. Reaction of! with PNB02CNHCH2-
CH2SH10 gave 4b (76%), which was converted to 6b in the usual way (20%, yield over 4
~ IV
steps). Hydrogenation of 6b gave 6c in 19%yield (purity 80%by IH NMR)~ ~
-1915-
4,5: a. RX =OAc
b. RX =SCH2CH2NHC02PNB
c. RX =SCH2-3-Pyr.
6: a. RX = OAc R' = PNB
b. RX = SCH2CH2NHC02PNB R' = PNB
c. RX = SCH2CH2NH2 R' = H
d. RX = SCH2-3-Pyr R' = PNB
e. RX = SCH2-3-Pyr R' = H
f. RX = SOCH2CH2NHC02PNB R' = PNB
g. RX = SOCH2CH2NH2 R' = H
h. RX = SOCH2-3-Pyr R' = PNB
i. RX = SOCH2-3-Pyr R' = H
j. RX = S02CH2CH2NHC02PNB R' = PNB
k. RX = H R' = H
1. RX = S02CH2-3-Pyr R' = PNB
m. RX = S02CH2-3-Pyr R' = H
-1916-
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REACTION CONDITIONS
2? 3: i. (CH3)2CHCH202CCl, Et3N, CH2CI2, -78°C. ii CH2N2,
-30°? -10°C. iii. HBr, -40°C.
3?4a: NaOAc, DMF, RT.
3?4b: PNB02CNHCH2CH2SH, i-Pr2NEt, CH2CI2, OOC.
3?4c: 3-PyrCH2SH, Et3N, CH2Cl2, OOC.
4? 5 : i PNB02CCH(OH)2' benzene, azeotropic reflux. ii SOCl2,
1? 8 Et3N, THF, -20°C. iii Ph3P, THF, RT.
5 ? 6: Toluene, 1%hydroquinone, reflux.
6b'd ? 6f,h: 1 eq. MCPBA, CH2Cl2, -30°C.
6b'd ? 6j,l: 2 eq. MCPBA, CH2CI2, OOC.
6b'd,f,h,j,l ? : Pd/C 10%(eq. amount w/w to 6), H2, THF, Phosphate
6c,e,g'i'k,m buffer pH 7.
3?7: (CH20H)2' PPTS, benzene, azeotropic reflux.
8?9 70%aq. HCI04, CH2C12, 8 min.
9? 10+11: CH3CN, RT, 16 hrs.
after RP-18 column chromatography and lyophilization. Though 6c was very unstable11, we~
were able to establish that the compound had a satisfactory antibacterial spectrum and had
improved renal dehydrogenase stability compared to the fluorinated thienamycin 1b3b. Encour-~
aged by this finding we set out to synthesize more analogues, soon to find out that the se-
quence 4 ? 5 is of limited value because of the incompatibility of many functional groups with~ ~
SOC12. So, clearly the synthetic sequence had to be adapted in such a way as to allow intro-
duction of the variable side chain at a later stage. Thus we protected bromoketone 3 as the
ketal 7 (77 %) which was transformed into phosphorane 8 (74 %). The ketal function in! was
very stable and deprotection turned out. to be a serious problem. After many unsuccessful at-
tempts we found that 8 could be hydrolyzed in CH2C12 solution by brief treatment with a large
excess of 70% aqueous HCI04 (99%)12. The resulting bromoketone was very unstable and was
best immediately reacted with mercaptan and base. A solution of 9 in CH3CN left overnight
gave 10 and 11 as main products. Reaction of 9 with 3-pyridylmethyl mercaptan and Et3N gave
5c (100%)which was cyclized to 6d (64%), which we had not been able to obtain by the original
sequence: 4c had perished in the second step of the Woodward sequence. Catalytic hydrogena-
tion of 6d did produce the expected carbapenem potassium salt 6e (3%), but this compound was~ ~
80 unstable that no biological data could be obtained. We then sought to find out if the sta-
bility of these compounds is influenced by the oxidation state of the sulfur in the side chain.
Oxidation of 6b and 6d with 1 eq. of MCPBA gave the sulfoxides 6f (51%) and 6h (61%); with 2~ ~ ~ ~
eq. MCPBA the sulfones 6j (41%) and 61 (47%) were obtained. Deprotection of the
'' ~~
-1917-
sulfoxides 6f and 6h and the sulfone 61 proceeded as usual to give 6g (15%), 6i (46%) and 6m~ ~ ~ ~ ~ ~
(47%), respectively; but the stability of these compounds was very similar to those of the par-
ent sulfides. Deprotection of 6j was accompanied by reduction of the allylic sulfone, giving
133-methylcarbapenem carboxylate 6k .~
Since it is possible that the instability of these carbapenems is due to the presence of a po-
tential leaving group on methyl we have now shifted our attention to aminoalkyl substituted
carbapenems and we will report on this in due course.
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